Drug Trial Radar · NCT00441558
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
Last checked: Nov 20, 2026Latest source record: Jun 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,723
Actual
Start
Feb 2007
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
FlibanserinDrug
flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Frequency of Adverse Events (Side Effects).Time frame: 52 weeks
Locations
196 sites in 2 countries. Site status is shown where the registry gives one.
511.84.01079 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.84.01193 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.84.01188 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
511.84.01110 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.84.01142 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.84.01157 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.84.01162 Boehringer Ingelheim Investigational Site
Little Rock, Alaska
511.84.01070 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.84.01191 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.84.01115 Boehringer Ingelheim Investigational Site
Tucson, Arizona
511.84.01013 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
511.84.01087 Boehringer Ingelheim Investigational Site
Berkeley, California
511.84.01077 Boehringer Ingelheim Investigational Site
Encinitas, California
511.84.01074 Boehringer Ingelheim Investigational Site
Fair Oaks, California
511.84.01104 Boehringer Ingelheim Investigational Site
Irvine, California
511.84.01037 Boehringer Ingelheim Investigational Site
La Jolla, California
511.84.01056 Boehringer Ingelheim Investigational Site
Sacramento, California
511.84.01195 Boehringer Ingelheim Investigational Site
Sacramento, California
511.84.01043 Boehringer Ingelheim Investigational Site
San Diego, California
511.84.01047 Boehringer Ingelheim Investigational Site
San Diego, California
511.84.01096 Boehringer Ingelheim Investigational Site
San Diego, California
511.84.01040 Boehringer Ingelheim Investigational Site
Stanford, California
511.84.01048 Boehringer Ingelheim Investigational Site
Tarzana, California
511.84.01017 Boehringer Ingelheim Investigational Site
Torrance, California
511.84.01173 Boehringer Ingelheim Investigational Site
Vista, California
511.84.01029 Boehringer Ingelheim Investigational Site
Walnut Creek, California
511.84.01137 Boehringer Ingelheim Investigational Site
Westlake Village, California
511.84.01090 Boehringer Ingelheim Investigational Site
Aurora, Colorado
511.84.01164 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.84.01184 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.84.01004 Boehringer Ingelheim Investigational Site
Englewood, Colorado
511.84.01006 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
511.84.01138 Boehringer Ingelheim Investigational Site
Farmington, Connecticut
511.84.01044 Boehringer Ingelheim Investigational Site
Groton, Connecticut
511.84.01016 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
511.84.01108 Boehringer Ingelheim Investigational Site
New Britain, Connecticut
511.84.01168 Boehringer Ingelheim Investigational Site
New London, Connecticut
511.84.01166 Boehringer Ingelheim Investigational Site
Newark, Delaware
511.84.01160 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
511.84.01065 Boehringer Ingelheim Investigational Site
Aventura, Florida
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.